Tang et al. reported that TGF-β1/Smad signaling inhibition led to a metabolic disorder of the urethral ECM and that activation of the TGF-β1/Smad signaling pathway had therapeutic effects on SUI [11]. This evidence concerns the gene TGFB1 and Other metabolic disease.